

# Ruth M O'regan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/949616/publications.pdf>

Version: 2024-02-01

50  
papers

1,998  
citations

430874

18  
h-index

330143

37  
g-index

51  
all docs

51  
docs citations

51  
times ranked

3490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-10-08: Assessment of risk factors for HER2+ breast cancer recurrence: A literature review. <i>Cancer Research</i> , 2022, 82, P2-10-08-P2-10-08.	0.9	0
2	A phase I study of talazoparib (<sc>BMN</sc> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<sc>NCI9782</sc>). <i>Cancer Medicine</i> , 2022, 11, 3969-3981.	2.8	11
3	Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition. <i>Journal of Clinical Oncology</i> , 2022, 40, 1142-1146.	1.6	3
4	Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?. <i>Cancer</i> , 2021, 127, 3302-3309.	4.1	3
5	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671.	13.2	34
6	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. <i>Science Translational Medicine</i> , 2021, 13, eabd4811.	12.4	48
7	Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. <i>Clinical Breast Cancer</i> , 2021, 21, 509-520.	2.4	13
8	Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 617-627.	2.5	12
9	Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 599-606.	2.5	11
10	Progress in breast cancer research amid the COVID-19 gloom. <i>Cancer</i> , 2020, 126, 3809-3810.	4.1	0
11	Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. <i>Cancer</i> , 2020, 126, 3400-3416.	4.1	19
12	Implementation of a chemotherapy stewardship process. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1243-1248.	1.0	0
13	Neratinib: an option for HER2-positive metastatic breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 15, 1-20.	0.3	0
14	Treatment goals in the management of HER2-positive metastatic breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 15, 3-6.	0.3	0
15	Neratinib: an option for HER2-positive metastatic breast cancer-Q&A. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 15, 15-17.	0.3	0
16	Neratinib in the early-stage/extended adjuvant breast cancer patient. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 12, 1-20.	0.3	0
17	Neratinib in early-stage breast cancer: clinical trial data. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 12, 7-10.	0.3	0
18	Neratinib in the early-stage/extended adjuvant breast cancer patient: Q&A. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 12, 16-17.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 188-196.	2.4	2
20	Race, breast cancer, and prognosis: Where biology is queen?. <i>Cancer</i> , 2019, 125, 3104-3106.	4.1	1
21	Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling. <i>Cancers</i> , 2019, 11, 2039.	3.7	19
22	The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 982-993.	0.9	50
23	Adjuvant Endocrine Therapy. <i>Cancer Treatment and Research</i> , 2018, 173, 15-29.	0.5	12
24	Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. <i>Clinical Breast Cancer</i> , 2018, 18, 347-352.	2.4	5
25	Social media and clinical trials: The pros and cons gain context when the patient is at the center. <i>Cancer</i> , 2018, 124, 4618-4621.	4.1	15
26	Hormone Receptor-Positive Breast Cancer Has Worse Prognosis in Male Than in Female Patients. <i>Clinical Breast Cancer</i> , 2017, 17, 356-366.	2.4	29
27	Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 279-287.	2.5	335
28	AR Signaling in Breast Cancer. <i>Cancers</i> , 2017, 9, 21.	3.7	81
29	African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 743-755.	2.5	14
30	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2016, 34, 2115-2124.	1.6	141
31	Role of the androgen receptor in triple-negative breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 186-93.	0.3	68
32	Optimizing Endocrine Therapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e56-e64.	4.9	21
33	FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. <i>Oncotarget</i> , 2015, 6, 4757-4772.	1.8	101
34	High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to Novel Nonanthracycline Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 31-36.	2.4	15
35	Triple-negative breast cancer in African-American women: disparities versus biology. <i>Nature Reviews Cancer</i> , 2015, 15, 248-254.	28.4	342
36	The role of CHFR as a predictive marker of response to taxane-based preoperative chemotherapy in triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1112-1112.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Phase 2 trial of trastuzumab and/or everolimus in hormone-resistant HER2-negative metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, 576-576.	1.6	0
38	Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.. Journal of Clinical Oncology, 2013, 31, 1007-1007.	1.6	2
39	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. Journal of Clinical Oncology, 2013, 31, 505-505.	1.6	34
40	Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology, 2013, 31, TPS650-TPS650.	1.6	1
41	Adherence rates to endocrine therapy among African American women with stage I-III, hormone receptor-positive breast cancer treated at Grady Memorial Hospital in Atlanta, Georgia.. Journal of Clinical Oncology, 2013, 31, e11582-e11582.	1.6	0
42	mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opinion on Therapeutic Targets, 2011, 15, 859-872.	3.4	31
43	Adjuvant anthracyclines: time for a change of heart?. Oncology, 2011, 25, 140, 142.	0.5	0
44	In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemotherapy and Pharmacology, 2010, 65, 697-706.	2.3	46
45	Endocrine Therapy for Metastatic Disease: Reversing Resistance. Current Breast Cancer Reports, 2010, 2, 114-119.	1.0	0
46	Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Research and Treatment, 2010, 123, 139-147.	2.5	75
47	Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer. Biomarkers, 2010, 15, 191-193.	1.9	7
48	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research and Treatment, 2009, 113, 357-370.	2.5	332
49	Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice. Clinical Cancer Research, 2006, 12, 2255-2263.	7.0	34
50	Final Results of a Phase II Trial of Preoperative TAC (Docetaxel/Doxorubicin/Cyclophosphamide) in Stage III Breast Cancer. Clinical Breast Cancer, 2005, 6, 163-168.	2.4	23